Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Operating Margin (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Operating Margin for 1 consecutive years, with 729044.44% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Operating Margin changed N/A year-over-year to 729044.44%, compared with a TTM value of 3626.41% through Dec 2024, changed N/A, and an annual FY2022 reading of 10225.39%, down 546110.0% over the prior year.
  • Operating Margin was 729044.44% for Q4 2024 at Summit Therapeutics, up from 1921.89% in the prior quarter.
  • Across five years, Operating Margin topped out at 729044.44% in Q4 2024 and bottomed at 1358.19% in Q1 2024.